Skip to main content
Figure 1 | BMC Endocrine Disorders

Figure 1

From: Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Figure 1

Changes in efficacy parameters (LOCF). (A) Change in HbA1c, (B) change in FPG, (C) percent change in body weight, (D) change in systolic BP, and (E) change in diastolic BP. LOCF, last observation carried forward; FPG, fasting plasma glucose; BP, blood pressure; LS, least squares; SE, standard error; CI, confidence interval; PBO, placebo; CANA, canagliflozin.

Back to article page